Overview Dividends

(GSK) GlaxoSmithKline - Ratings and Ratios

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US37733W2044

Vaccines, Specialty Medicines, General Medicines, Respiratory, Oncology

Pharmaceuticals
Market Cap in USD: 99,249m

IPO / Inception: 1986-07-09
Return 12m vs S&P 500: 31.1%

EPS (Earnings per Share)

EPS CAGR: -47.24%
EPS Trend: -12.3%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -2.85%
Rev. Trend: 19.3%

Last SUE: 0.12
Qual. Beats: 0

Dividends

Dividend Yield	3.34%
Yield on Cost 5y	5.50%
Yield CAGR 5y	-11.31%
Payout Consistency	90.9%
Payout Ratio	37.4%

Risk via 5d forecast
Volatility	23.7%
Value at Risk 5%th	36.6%
Relative Tail Risk	-6.23%

Reward TTM
Sharpe Ratio	1.52
Alpha	46.94
CAGR/Max DD	0.61

Character TTM
Hurst Exponent	0.383
Beta	0.238
Beta Downside	0.174

Drawdowns 3y
Max DD	28.46%
Mean DD	8.39%
Median DD	6.88%

Description: GSK GlaxoSmithKline December 03, 2025

GSK plc (NYSE:GSK) develops, manufactures, and markets vaccines, specialty medicines, and general medicines across the UK, US, and global markets, organized into Commercial Operations and Total R&D segments. Its specialty portfolio spans oncology, respiratory-immunology, inflammation, and HIV-related inhaled therapies, while its vaccine suite includes products for shingles, RSV, seasonal flu, HPV, and a broad range of pediatric and adult diseases. The firm also supplies general medicines for asthma, COPD, bacterial infections, BPH, allergic rhinitis, and inflammatory skin conditions.

Key recent metrics: FY2023 revenue was $46.8 billion, with a dividend yield near 5.5 % and a payout ratio of ~70 %, reflecting its status as a high-yielding pharma dividend. R&D intensity remains high, with ~12 % of sales reinvested in research (≈$5.6 billion in FY2023), supporting a pipeline that includes the RSV vaccine candidate (RSVpreF) and several oncology assets in Phase III trials. A primary sector driver is the aging global population, which sustains demand for vaccines and chronic-disease therapeutics, while pricing pressures from health-care payers and inflationary cost environments introduce earnings volatility.

Strategic collaborations include an mRNA vaccine partnership with CureVac and an alliance with AN2 Therapeutics to develop new tuberculosis therapies, both aimed at diversifying GSK’s pipeline beyond its traditional small-molecule and protein-based products.

For a deeper dive into GSK’s valuation metrics and peer comparisons, you might find ValueRay’s analyst toolkit useful.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (5.49b TTM) > 0 and > 6% of Revenue (6% = 1.93b TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA -2.94pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -14.62% (prev -13.29%; Δ -1.33pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 8.60b > Net Income 5.49b (YES >=105%, WARN >=100%)

Net Debt (19.46b) to EBITDA (10.80b) ratio: 1.80 <= 3.0 (WARN <= 3.5)

Current Ratio 0.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (2.05b) change vs 12m ago 0.54% (target <= -2.0% for YES)

Gross Margin 72.27% (prev 71.55%; Δ 0.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 45.75% (prev 53.94%; Δ -8.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 11.68 (EBITDA TTM 10.80b / Interest Expense TTM 657.0m) >= 6 (WARN >= 3)

Altman Z'' 1.18

(A) -0.06 = (Total Current Assets 24.02b - Total Current Liabilities 28.72b) / Total Assets 82.58b

(B) 0.16 = Retained Earnings (Balance) 13.48b / Total Assets 82.58b

(D) 0.28 = Book Value of Equity 17.05b / Total Liabilities 61.37b

Total Rating: 1.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 76.91

1. Piotroski 6.0pt

2. FCF Yield 6.31%

3. FCF Margin 18.51%

4. Debt/Equity 1.10

5. Debt/Ebitda 1.80

6. ROIC - WACC (= 30.53)%

7. RoE 29.72%

8. Rev. Trend 19.29%

9. EPS Trend -12.33%

What is the price of GSK shares?

As of January 09, 2026, the stock is trading at USD 50.22 with a total of 4,283,271 shares traded.
Over the past week, the price has changed by +1.19%, over one month by +3.61%, over three months by +16.86% and over the past year by +55.19%.

Is GSK a buy, sell or hold?

GlaxoSmithKline has received a consensus analysts rating of 2.88. Therefor, it is recommend to hold GSK.

Strong Buy: 1
Buy: 0
Hold: 5
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the GSK price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	49.4	-1.7%
Analysts Target Price	49.4	-1.7%
ValueRay Target Price	60.4	20.3%

GSK Fundamental Data Overview January 03, 2026

Market Cap GBP = 73.70b (99.25b USD * 0.7426 USD.GBP)
P/E Trailing = 13.6983
P/E Forward = 9.4607
P/S = 3.0855
P/B = 4.549
P/EG = 0.4203
Beta = 0.23
Revenue TTM = 32.17b GBP
EBIT TTM = 7.67b GBP
EBITDA TTM = 10.80b GBP
Long Term Debt = 14.89b GBP (from longTermDebt, last quarter)
Short Term Debt = 3.84b GBP (from shortTermDebt, last quarter)
Debt = 23.90b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.46b GBP (from netDebt column, last quarter)
Enterprise Value = 94.30b GBP (73.70b + Debt 23.90b - CCE 3.30b)
Interest Coverage Ratio = 11.68 (Ebit TTM 7.67b / Interest Expense TTM 657.0m)
FCF Yield = 6.31% (FCF TTM 5.95b / Enterprise Value 94.30b)
FCF Margin = 18.51% (FCF TTM 5.95b / Revenue TTM 32.17b)
Net Margin = 17.08% (Net Income TTM 5.49b / Revenue TTM 32.17b)
Gross Margin = 72.27% ((Revenue TTM 32.17b - Cost of Revenue TTM 8.92b) / Revenue TTM)
Gross Margin QoQ = 73.58% (prev 72.89%)
Tobins Q-Ratio = 1.14 (Enterprise Value 94.30b / Total Assets 82.58b)
Interest Expense / Debt = 0.70% (Interest Expense 167.0m / Debt 23.90b)
Taxrate = 12.70% (312.0m / 2.46b)
NOPAT = 6.70b (EBIT 7.67b * (1 - 12.70%))
Current Ratio = 0.84 (Total Current Assets 24.02b / Total Current Liabilities 28.72b)
Debt / Equity = 1.10 (Debt 23.90b / totalStockholderEquity, last quarter 21.74b)
Debt / EBITDA = 1.80 (Net Debt 19.46b / EBITDA 10.80b)
Debt / FCF = 3.27 (Net Debt 19.46b / FCF TTM 5.95b)
Total Stockholder Equity = 18.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.81% (Net Income 5.49b / Total Assets 82.58b)
RoE = 29.72% (Net Income TTM 5.49b / Total Stockholder Equity 18.49b)
RoCE = 22.98% (EBIT 7.67b / Capital Employed (Equity 18.49b + L.T.Debt 14.89b))
RoIC = 35.88% (NOPAT 6.70b / Invested Capital 18.66b)
WACC = 5.35% (E(73.70b)/V(97.60b) * Re(6.89%) + D(23.90b)/V(97.60b) * Rd(0.70%) * (1-Tc(0.13)))
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.19%
[DCF Debug] Terminal Value 83.94% ; FCFF base≈5.93b ; Y1≈4.81b ; Y5≈3.35b
Fair Price DCF = 41.10 (EV 102.36b - Net Debt 19.46b = Equity 82.90b / Shares 2.02b; r=6.0% [WACC]; 5y FCF grow -22.74% → 3.0% )
EPS Correlation: -12.33 | EPS CAGR: -47.24% | SUE: -4.0 | # QB: 0
Revenue Correlation: 19.29 | Revenue CAGR: -2.85% | SUE: 0.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.20 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=4.66 | Chg30d=-0.145 | Revisions Net=+3 | Growth EPS=+8.9% | Growth Revenue=+5.3%

Additional Sources for GSK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle